Lung Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine.
Covering three important studies:
ADAURA trial update with increase OS with adjuvant Osimertinib
KEYNOTE 789 - Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant
KEYNOTE 671 - Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
#oncbrothers #asco #2023 #lungcancer #oncology #drcharuaggarwal #pennmedicine
Website: www.oncbrothers...
Twitter: / oncbrothers
Contact us at [e-mail]

[@dr.jovitamartindaniel-English]

Very useful discussion Oncology brothers!

[@terrencek7881]

👉 Promo'SM